HYBRID EVENT: You can participate in person at Paris, France or Virtually from your home or work.
COVID-19 Drug Development
COVID-19 drug development is a research process to discover a preventative and therapeutic prescription of drugs that would control the severity of coronavirus disease. From 2020 to 2021, various drug companies, biotechnology firms, university research groups, and health organizations were started developing over 600 potential therapies for corona virus disease with various stages of preclinical or clinical research, with 391 therapeutic candidates in clinical trials, as of January 2021.
PDDS 2022 Speakers
Victoria Demina
NEUWAY Pharma GmbH, GermanySubmit your abstract Today
Title : Drug Delivery to the Brain using Engineered Protein Capsules (EnPCs®)
Victoria Demina, NEUWAY Pharma GmbH, Germany
Title : NEWER ADVANCES OF ANTI –HIV THERAPY
Bhuvanesh baniya, Jai Narain Vyas University Jodhpur, India
Title : Insulin Resistance Associated Alzheimer Disease Condition in Rats is ameliorated via Epigenetic Regulation and Autophagy Modulation
Violina Kakoty, Birla Institute of Technology and Science-Pilani, India
Title : SELF MICROEMULSIFYING SYSTEMS BASED TOPICAL LIPSTICK OF ANTIFUNGAL AGENT
Bhupendra Gopalbhai Prajapati, Ganpat University, Shree S.K.Patel College of Pharmaceutical Education and Research, India
Title : Sol-gel, phase inversion precipitation and microfluidic systems for controlled delivery of pharmaceuticals and bioactive compounds in nutraceuticals and nano nutraceuticals
Sandile Phinda Songca, University of KwaZulu-Natal, South Africa
Title : The e?ects of Anethum graveolens (dill) supplementation on lipid profile and glycemic control: A systematic review and meta-analysis of randomized controlled trials
Seyed Mohammad Mousavi, Tehran University of Medical Sciences, Tehran, Iran., Iran (Islamic Republic of)